The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

Annals of the Rheumatic Diseases

Volumn 75, Issue 5, 2016, Pages 795-810

  Skorpen, Carina Götestam ^a,b,c   Hoeltzenbein, Maria ^d   Tincani, Angela ^e   Fischer Betz, Rebecca ^f   Elefant, Elisabeth ^g   Chambers, Christina ^h   Da Silva, Josè ⁱ   Nelson Piercy, Catherine ^j   Cetin, Irene ^k   Costedoat Chalumeau, Nathalie ^l,m   Dolhain, Radboud ⁿ   Förger, Frauke ^o   Khamashta, Munther ^j   Ruiz Irastorza, Guillermo ^p   Zink, Angela ^d   Vencovsky, Jiri ^q   Cutolo, Maurizio ^r   Caeyers, Nele ^s   Zumbühl, Claudia ^t   Østensen, Monika ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c Alesund Hospital   (Norway)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g ARMAND TROUSSEAU HOSPITAL   (France)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^j ST THOMAS HOSPITAL   (United Kingdom)

^k UNIVERSITY OF MILAN   (Italy)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o UNIVERSITY OF BERN   (Switzerland)

^p HOSPITAL DE CRUCES   (Spain)

^q INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^r UNIVERSITY OF GENOA   (Italy)

^s EULAR Social Leagues Patients' Representative   (Belgium)

^t EULAR Social Leagues Patients' representative   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BELIMUMAB; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN G; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; TERATOGENIC AGENT; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; BIOLOGICAL PRODUCT;

CONGENITAL MALFORMATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; LACTATION; LOW BIRTH WEIGHT; PATIENT SAFETY; PERINATAL PERIOD; PLACENTAL TRANSFER; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TERATOGENICITY; ABNORMALITIES, DRUG-INDUCED; CONSENSUS DEVELOPMENT; DELPHI STUDY; FEMALE; FETOMATERNAL TRANSFUSION; NEWBORN; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PREPREGNANCY CARE; PROCEDURES; RHEUMATIC DISEASES;

ABNORMALITIES, DRUG-INDUCED; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DELPHI TECHNIQUE; FEMALE; HUMANS; INFANT, NEWBORN; LACTATION; MATERNAL-FETAL EXCHANGE; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RHEUMATIC DISEASES;

EID: 84959378744     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208840     Document Type: Review

References (76)

1. Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:209.
2. Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008;47(Suppl 3): 28-31.
3. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
4. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
5. Ghogomu EA, Maxwell LJ, Buchbinder R, et al. Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses. J Rheumatol 2014;41:194-205.
6. Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Asses Res Eval 2007;12:1-8.
7. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg 2011;128:305-10.
8. Goldet G, Howick J. Understanding GRADE: An introduction. J Evid Based Med 2013;6:50-4.
9. Jeremy H, Iain C, Paul G. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) table of evidence. Background document. http://www.cebm.net/index.aspx?o=5653 (accessed Jan 2014).
10. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine-levels of evidence (March 2009). Centre for Evidence Based Medicine Web site. http://www.cebm.net/index.aspx?o=5653 (accessed Jan 2014).
11. Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: A prospective cohort study. BJOG 2013;120:948-59.
12. Edwards DR, Aldridge T, Baird DD, et al. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol 2012;120:113-22.
13. van Gelder MM, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: A prospective cohort study. Plos One 2011;6:e22174.
14. Daniel S, Koren G, Lunenfeld E, et al. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ 2014;186:E177-E82.
15. Daniel S, Matok I, Gorodischer R, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 2012;39:2163-9.
16. Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: A cohort study among 150, 000 pregnant women and expectant fathers. Scand J Rheumatol 2012;41:196-201.
17. Nakhai-Pour HR, Broy P, Sheehy O, et al. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011;183:1713-20.
18. Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus 2010;19:1665-73.
19. Bay Bjørn AM, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther 2014;21:73-80.
20. Gomaa MF, Elkholy AG, El-Said MM, et al. Combined oral prednisolone and heparin versus heparin: The effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet 2014;290:757-62.
21. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011;183:796-804.
22. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008;103:1203-9.
23. Tang AW, Alfirevic Z, Turner MA, et al. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod 2013;28:1743-52.
24. Diav-Citrin O, Blyakhman S, Shechtman S, et al. Pregnancy outcome following in utero exposure to hydroxychloroquine: A prospective comparative observational study. Reprod Toxicol 2013;39:58-62.
25. Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7.
26. Koh JH, Ko HS, Kwok SK, et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015;24:210-7.
27. Cooper WO, Cheetham TC, Li DK, et al. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. Lupus 2014;66:444-50.
28. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126:76-82.
29. de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: Results of a national prospective study. Arthritis Rheum 2009;60:3196-206.
30. Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis. Reprod Toxicol 2008;25:271-5.
31. Nørgård B, Pedersen L, Christensen LA, et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: A Danish nationwide cohort study. Am J Gastroenterol 2007;102:1406-13.
32. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503.
33. Karadag O, Kilic L, Erbil AA, et al. Pregnancy outcomes of rheumatic patients with pre/peri gestational leflunomide exposure.. Ann Rheum Dis 2013;72(Suppl 3): A896-A7.
34. Alami Z, Cissoko H, Ahid S, et al. Pregnancy outcomes after maternal use of azathioprine: A French cohort Study.. Fundam Clin Pharmacol 2013;27:43.
35. Ban L, Tata LJ, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 2014;146:76-84.
36. Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:433-40.
37. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res Part A Clin Mol Teratol 2009;85:647-54.
38. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011;60:198-203.
39. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res Part A Clin Mol Teratol 2007;79:696-701.
40. Julsgaard M, Norgaard M, Hvas CL, et al. Influence of medical treatment, smoking and disease activity on pregnancy outcomes in Crohn's disease. Scand J Gastroenterol 2014;49:302-8.
41. Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study. Aliment Pharmacol Ther 2007;25:73-81.
42. Shim L, Eslick GD, Simring AA, et al. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011;5: 234-8.
43. Martin MC, Barbero P, Groisman B, et al. Methotrexate embryopathy after exposure to low weekly doses in early pregnancy. Reprod Toxicol 2014;43:26-9.
44. Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: A prospective multicenter cohort study. Reprod Toxicol 2014;66:1101-10.
45. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: Results of an international registry. Am J Clin Oncol 2010;33:221-8.
46. Silva CA, Hilario MO, Febronio MV, et al. Pregnancy outcome in juvenile systemic lupus erythematosus: A Brazilian multicenter cohort study. J Rheumatol 2008;35:1414-8.
47. Mohamed-Ahmed O, Nelson-Piercy C, Bramham K, et al. Pregnancy outcomes in liver and cardiothoracic transplant recipients: A UK national cohort study. Plos One 2014;9:e89151.
48. Nulman I, Sgro M, Barrera M, et al. Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant. Paediatr Drugs 2010;12:113-22.
49. Perales-Puchalt A, Vila Vives JM, Lopez Montes J, et al. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. J Matern Fetal Neonatal Med 2012;25:1363-6.
50. Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 2012;158 A:588-96.
51. Ben-Chetrit E, Ben-Chetrit A, Berkun Y, et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken) 2010;62:143-8.
52. Diav-Citrin O, Shechtman S, Schwartz V, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010;203:144.e1-e6.
53. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009;104:223-5.
54. Heilmann L, Schorch M, Hahn T, et al. Pregnancy outcome in women with antiphospholipid antibodies: Report on a retrospective study. Semin Thromb Hemost 2008;34:794-802.
55. Perricone R, De Carolis C, Kröegler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford) 2008;47:646-51.
56. Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: Three-center study. Scand J Gastroenterol 2013;48:951-8.
57. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study. Reprod Toxicol 2014;43:78-84.
58. Giacuzzo S, Padovan M, Capucci R, et al. Pregnancy outcome of mothers with rheumatic diseases exposed to biological agent during pregnancy: A single-centre study. Ann Rheum Dis 2014;73(Suppl 2):414.
59. Kalari S, Granath F, Guo CY, et al. Pregnancy outcomes in women with rheumatologic conditions exposed to infliximab. Ann Rheum Dis 2014;73(Suppl 2):482-3.
60. Kelly O, Hartery K, Boland K, et al. TNF alpha inhibitor use in pregnancy: Experience in a European cohort. J Crohn's Colitis 2014; 8:S204-S05.
61. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92.
62. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54.
63. Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcomein anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:363-73.
64. Verstappen SM, King Y, Watson KD, et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823-6.
65. Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: A prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39.
66. Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013;11:318-21.
67. Chambers C, Johnson D, Luo Y, et al. Pregnancy outcome in women treated with adalimumab for the treatment of rheumatoid arthritis: An update on the otis autoimmune diseases in pregnancy project.. Am J Gastroenterol 2014;109(Suppl): S638.
68. Johnson D, Luo Y, Jones KL, et al. Pregnancy outcomes in women exposed to adalimumab: An update on the autoimmune diseases in pregnancy project.. Arthritis Rheum 2011;1(Suppl S10):1874.
69. Sinclair S, Cunnington M, Messenheimer J, et al. Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. Pharmacoepidemiol Drug Saf 2014;23:779-86.
70. Nordeng H, Havnen GC, Spigset O. Drug use and breastfeeding. Tidsskr Nor Laegeforen 2012;132:1089-93.
71. Mahadevan U, Martin CF, Sandler RS, et al. Piano: A 1000 patient prospective registry of pregnancy outcomes in women with ibd exposed to immunomodulators and biologic therapy. Gastroenterology 2012;1:S149.
72. Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010;184:1968-76.
73. Sarvas H, Seppala I, Kurikka S, et al. Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 1993;13:145-51.
74. Begg EJ, Atkinson HC, Duffull SB. Prospective evaluation of a model for the prediction of milk: Plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmacol 1992;33:501-5.
75. Dewulf L. Medicines in pregnancy-women and children first? Time for a coalition to address a substantial patient need. Ther Innov Regul Sci 2013;47:528-32.
76. Cush JJ, Kavanaugh A. Editorial: Pregnancy and rheumatoid arthritis-do not let the perfect become the enemy of the good. Curr Opin Rheumatol 2014;26:299-301.